China, a Fast-Growing, Unique Market

As the world’s second-largest market (after the US) and the only major market growing in the high single-digits annually, China is attracting increasing numbers of multinational companies (MNCs) vying aggressively for market share in the innovative drugs sector.
With a decade of sustained government support, including policy reform, talent development, and investment, we see China becoming a “wave one” country for innovative product launches with companies pivoting toward innovation-driven portfolios.
China is a unique market with localized policies and restricted regulations. To conduct business successfully in China, an MNC needs to internalize insights into disease management and obtain a deep understanding of the healthcare system in China.